Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
Sandra P. D’Angelo, Michelle R. Mahoney, Brian Andrew Van Tine, et al.
The Lancet Oncology (2018) Vol. 19, Iss. 3, pp. 416-426
Open Access | Times Cited: 631

Showing 1-25 of 631 citing articles:

B cells are associated with survival and immunotherapy response in sarcoma
Florent Petitprez, Aurélien de Reyniès, Emily Z. Keung, et al.
Nature (2020) Vol. 577, Iss. 7791, pp. 556-560
Open Access | Times Cited: 1531
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 822
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
Yucai Wang, Shouhao Zhou, Fang Yang, et al.
JAMA Oncology (2019) Vol. 5, Iss. 7, pp. 1008-1008
Open Access | Times Cited: 681
Soft‐tissue sarcoma in adults: An update on the current state of histiotype‐specific management in an era of personalized medicine
Adriana C. Gamboa, Alessandro Gronchi, Kenneth Cardona
CA A Cancer Journal for Clinicians (2020) Vol. 70, Iss. 3, pp. 200-229
Open Access | Times Cited: 419
Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs
Chenglong Chen, Lu Xie, Tingting Ren, et al.
Cancer Letters (2020) Vol. 500, pp. 1-10
Closed Access | Times Cited: 375
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial
Breelyn A. Wilky, Matteo Trucco, Ty K. Subhawong, et al.
The Lancet Oncology (2019) Vol. 20, Iss. 6, pp. 837-848
Closed Access | Times Cited: 316
Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy
Anastasia Constantinidou, Constantinos Alifieris, Dimitrios T. Trafalis
Pharmacology & Therapeutics (2018) Vol. 194, pp. 84-106
Closed Access | Times Cited: 292
T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
Smita S. Chandran, Christopher A. Klebanoff
Immunological Reviews (2019) Vol. 290, Iss. 1, pp. 127-147
Open Access | Times Cited: 255
Enterocolitis due to immune checkpoint inhibitors: a systematic review
Émilie Soularue, Patricia Lepage, Jean Frederic Colombel, et al.
Gut (2018) Vol. 67, Iss. 11, pp. 2056-2067
Closed Access | Times Cited: 219
Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
Lara E. Davis, Vanessa Bolejack, Christopher W. Ryan, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 16, pp. 1424-1431
Open Access | Times Cited: 211
Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies
Rodolfo Daniel Cervantes‐Villagrana, Damaris Albores‐García, Alberto R. Cervantes-Villagrana, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 205
Nanoparticle‐based photothermal and photodynamic immunotherapy for tumor treatment
Xiaoyang Hou, Yingkai Tao, Yanyu Pang, et al.
International Journal of Cancer (2018) Vol. 143, Iss. 12, pp. 3050-3060
Open Access | Times Cited: 200
Immuno-genomic landscape of osteosarcoma
Chia-Chin Wu, Hannah C. Beird, J. Andrew Livingston, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 185
Immune checkpoint inhibitors: The linchpins of modern immunotherapy
Breelyn A. Wilky
Immunological Reviews (2019) Vol. 290, Iss. 1, pp. 6-23
Closed Access | Times Cited: 177
The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity
Alexandra Schnell, Lloyd Bod, Asaf Madi, et al.
Cell Research (2020) Vol. 30, Iss. 4, pp. 285-299
Open Access | Times Cited: 175
Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution
Vaia Florou, Andrew E. Rosenberg, Eric Wieder, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 158
Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab
Ciara M. Kelly, Cristina R. Antonescu, Timothy G. Bowler, et al.
JAMA Oncology (2020) Vol. 6, Iss. 3, pp. 402-402
Open Access | Times Cited: 156
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab
Emily Z. Keung, Melissa Burgess, Ruth Salazar, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 6, pp. 1258-1266
Open Access | Times Cited: 153
Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets
Benjamin A. Nacev, Francisco Sánchez-Vega, Shaleigh Smith, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 123
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
Michael J. Wagner, Megan Othus, Sandip Pravin Patel, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 8, pp. e002990-e002990
Open Access | Times Cited: 110
Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma
Mrinal M. Gounder, Narasimhan P. Agaram, Sally E. Trabucco, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 107
Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment
Hailong Tian, Jiangjun Cao, Bowen Li, et al.
Bone Research (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 103
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial
Neeta Somaiah, Anthony P. Conley, Edwin R. Parra, et al.
The Lancet Oncology (2022) Vol. 23, Iss. 9, pp. 1156-1166
Closed Access | Times Cited: 99
Recent and Ongoing Research into Metastatic Osteosarcoma Treatments
Michael A. Harris, Christine J. Hawkins
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3817-3817
Open Access | Times Cited: 83
Blockade of beta-adrenergic receptors reduces cancer growth and enhances the response to anti-CTLA4 therapy by modulating the tumor microenvironment
Klaire Yixin Fjæstad, Anne Mette Askehøj Rømer, Victor Goitea, et al.
Oncogene (2022) Vol. 41, Iss. 9, pp. 1364-1375
Open Access | Times Cited: 72
Page 1 - Next Page

Scroll to top